Countdown to the introduction of a norovirus vaccine

Noroviruses are believed to make up half of all food-borne disease outbreaks in the United States, causing incapacitating (and often violent) stomach flu. These notorious human pathogens are responsible for 90 percent of epidemic nonbacterial outbreaks of gastroenteritis around the world.

On Friday, February 17, 2012, Charles Arntzen, ASU Regents' professor, and professor in the Center for Infectious Diseases and at the Biodesign Institute will deliver a lecture entitled Countdown to the Introduction of a Norovirus Vaccine. The talk will take place during the American Association for the Advancement of Science's annual meeting in Vancouver, BC.

Arntzen's lecture is part of a special topical seminar: Norovirus—The Modern Scourge of Food and Family.

The seminar title is well chosen—noroviruses are extremely contagious, readily passing from person to person, particularly among those living in the closed quarters of dormitories, nursing homes, child care centers, military bases, and cruise ships. Infections can result from contact with virus particles dispersed in the air or from the ingestion of even tiny quantities of contaminated food. Further, even vigorous hand washing or the use of alcohol wipes or gels may be ineffective in combating norovirus transmission. Noroviruses can persist in a transmissible state for days or weeks even in those who are asymptomatic or are recovering from the disease.

Arntzen will speak about the prospects for a successful vaccine to prevent norovirus infection, based on Virus-Like Particles (VLPs), which are able to mimic actual noroviruses, stimulating a robust immune response, without producing disease symptoms. Due to the frequent mutation of noroviruses, vaccine candidates will need to be adaptable for alternate strains of the pathogen—much the way current vaccines for influenza are modified to keep pace with viral evolution. New strategies for formulating and biomanufacturing such vaccines offer renewed hope for norovirus vaccine development in the near future.

add to favorites email to friend print save as pdf

Related Stories

Vaccine against epidemic gastroenteritis being tested

Dec 09, 2011

(Medical Xpress) -- A new vaccine is being tested in the US that may protect against the norovirus, which causes "stomach flu" or acute viral gastroenteritis, that can occur in confined living settings such as cruise ships, ...

Recommended for you

Poll: Many doubt hospitals can handle Ebola

18 minutes ago

A new poll finds most Americans have some confidence that the U.S. health care system will prevent Ebola from spreading in this country, but they're not so sure their local hospital can safely handle a patient.

Number of Ebola cases nears 10,000

35 minutes ago

The number of people with Ebola is set to hit 10,000 in West Africa, the World Health Organization said, as the scramble to find a cure gathered pace.

'Breath test' shows promise for diagnosing fungal pneumonia

1 hour ago

Many different microbes can cause pneumonia, and treatment may be delayed or off target if doctors cannot tell which bug is the culprit. A novel approach—analyzing a patient's breath for key chemical compounds made by the ...

Where Ebola battles are won

10 hours ago

(HealthDay)—Four hospitals that are home to advanced biocontainment facilities have become America's ground zero in the treatment of Ebola patients.

User comments